Glycominds Ltd. (TASE: GLCM), which develops tests to identify multiple sclerosis and its severity, has signed two agreements to join clinical trials for multiple sclerosis that are taking place in the US.

The goal of these trials is to examine different parameters for treating multiple sclerosis. At the same time, Glycominds will examine its test's ability to predict the disease's rate of progression.

The first trial includes 246 patients and will be performed in cooperation with the American non-profit ACP.

ACP has budgeted a few million shekels to support Glycominds' trials. The trial will examine whether Glycominds' test can diagnose multiple sclerosis in cases where the results from an initial test were negative.

Glycominds' test will also be integrated into a 115-patient trial at a research hospital in Ottawa, Canada, to see whether it can predict the progression rate of the disease.

In afternoon trading on the TASE, the company's share price was up 1.87% to NIS 1.04.

Published by Globes [online], Israel business news - www.globes-online.com - on July 6, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011